Abstract 2816
Background
Breast cancer is the leading cancer in the female population and one of the most common causes of cancer deaths in women. Improved treatment and the implementation of mammography screening have contributed to substantial reductions in breast cancer mortality over recent decades. The main goal of this study was to evaluate 10-year results of the Breast Cancer Screening Program in Ugra since 2007.
Methods
Biannual mammography screening covers women 40 years old using single reading of two-view mammography. Screening data were obtained from the reports for the State Healthcare Department. Data on female population, breast cancer cases (invasive and in situ) and deaths were provided by the State Cancer Registry and State Information Centre. We studied expected absolute incidence and mortality from breast cancer were calculated over the years 2002-16. Expected absolute number of tumours T1N0M0 and with size over 20 mm detected among women 40+ were calculated over the period in question. Expected number assumed constant rate in pre/post screening epochs and its changes were only due to population size. Rate estimated using pre-screening epoch and were age-adjusted.
Results
During 2007-16 within the Program, 451139 women were screened. The screening coverage rate in the 2015-16 round was 41% (144777 women). 13464 (9.3%) of those screened were referred for further assessment. The screen detection rate was 3.5 per 1000 screened (1582 breast cancer cases). The test sensitivity for the first round was estimated as 80%. The observed T1N0M0 in 2016 was 126 compared with 73 expected (42% increase). The observed number of breast cancers more than 2cm was 231 compared with 292 expected (26% reduction). Breast cancer mortality in 2016 was 119 compared with 187 expected (57.5% reduction) using absolute mortality results.
Conclusions
Trends suggest that mammographic screening in Ugra has contributed to a significant improvement in the early disease diagnosis, and breast cancer mortality has fallen. Improved screening coverage s needed.
Clinical trial identification
Legal entity responsible for the study
Khanty-Mansiysk State Medical Academy.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.